Page 1 | Search Results | Blood Advances | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

Aaron T. Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Alessandro M. Vannucchi, Rami Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam J. Mead, Jason Gotlib, Shelonitda Rose, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, Huijing Jiang, Jeanne M. Palmer, Kelly McCaul, Vincent Ribrag, Francesco Passamonti

Blood Adv (2024) 8 (17): 4511–4522.

https://doi.org/10.1182/bloodadvances.2024012939

Published: 2024

Includes: Supplemental data

Journal Articles

Inference of genomic lesions from single-cell RNA-seq in myeloma improves functional intraclonal and interclonal analysis

Blood Adv (2024) 8 (15): 3972–3984.

https://doi.org/10.1182/bloodadvances.2023012409

Published: 2024

Includes: Supplemental data

Journal Articles

Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis

Bruno Fattizzo, Giacinto Luca Pedone, Caterina Brambilla, Loredana Pettine, Anna Zaninoni, Francesco Passamonti, Wilma Barcellini

Blood Adv (2024) 8 (5): 1322–1327.

https://doi.org/10.1182/bloodadvances.2023011798

Published: 2024

Includes: Supplemental data

Journal Articles

COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

Blood Adv (2022) 6 (13): 3870–3874.

https://doi.org/10.1182/bloodadvances.2022007357

Published: 2022

Includes: Supplemental data

Journal Articles

COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

Blood Adv (2022) 6 (7): 2427–2433.

https://doi.org/10.1182/bloodadvances.2021005616

Published: 2022

Journal Articles

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Blood Adv (2022) 6 (6): 1855–1864.

https://doi.org/10.1182/bloodadvances.2021006889

Published: 2022

Includes: Supplemental data

Journal Articles

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study

John Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El-Galaly, Aaron Gerds, Vikas Gupta, Brian Higgins, Kathrin Wonde, Candice Jamois, Bruno Kovic, Ling-Yuh Huw, Sudhakar Katakam, Margherita Maffioli, Ruben Mesa, Jeanne Palmer, Marta Bellini, David M. Ross, Alessandro M. Vannucchi, Abdulraheem Yacoub

Blood Adv (2022) 6 (4): 1162–1174.

https://doi.org/10.1182/bloodadvances.2021006043

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Paola Guglielmelli, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Chiara Maccari, Barbara Mora, Elisa Rumi, Ana Triguero, Maria Chiara Finazzi, Helna Pettersson, Chiara Paoli, Francesco Mannelli, Daniele Vanni, Alessandro Rambaldi, Francesco Passamonti, Alberto Alvarez-Larràn, Bjorn Andreasson, Alessandro M. Vannucchi, Tiziano Barbui

Blood Adv (2022) 6 (2): 373–375.

https://doi.org/10.1182/bloodadvances.2021006006

Published: 2022

Includes: Supplemental data

Journal Articles

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Carlo Visco, Luigi Marcheselli, Roberto Mina, Marianna Sassone, Anna Guidetti, Domenico Penna, Chiara Cattaneo, Valentina Bonuomo, Alessandro Busca, Andrés José María Ferreri, Riccardo Bruna, Luigi Petrucci, Roberto Cairoli, Marco Salvini, Lorenza Bertù, Marco Ladetto, Sofia Pilerci, Antonello Pinto, Safaa Ramadan, Francesco Marchesi, Michele Cavo, Luca Arcaini, Elisa Coviello, Alessandra Romano, Pellegrino Musto, Massimo Massaia, Nicola Fracchiolla, Monia Marchetti, Annamaria Scattolin, Maria Chiara Tisi, Antonio Cuneo, Matteo Della Porta, Livio Trentin, Marco Turrini, Filippo Gherlinzoni, Agostino Tafuri, Sara Galimberti, Monica Bocchia, Valeria Cardinali, Daniela Cilloni, Alessandro Corso, Daniele Armiento, Luigi Rigacci, Elettra Ortu La Barbera, Carlo Gambacorti-Passerini, Giuseppe Visani, Daniele Vallisa, Adriano Venditti, Carmine Selleri, Annarita Conconi, Patrizia Tosi, Francesco Lanza, Anna Candoni, Mauro Krampera, Paolo Corradini, Francesco Passamonti, Francesco Merli, on behalf of the ITA-HEMA-COV investigators

Blood Adv (2022) 6 (1): 327–338.

https://doi.org/10.1182/bloodadvances.2021005691

Published: 2022

Includes: Supplemental data

Journal Articles

Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis

Blood Adv (2021) 5 (5): 1452–1462.

https://doi.org/10.1182/bloodadvances.2020003614

Published: 2021

Includes: Supplemental data

Journal Articles

Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses

Pierre-Edouard Debureaux, Bruno Cassinat, Juliette Soret-Dulphy, Barbara Mora, Emmanuelle Verger, Nabih Maslah, Aurelie Plessier, Pierre-Emmanuel Rautou, Isabelle Ollivier-Hourman, Victor De Ledinghen, Odile Goria, Christophe Bureau, Claudia Siracusa, Dominique Valla, Stephane Giraudier, Francesco Passamonti, Jean-Jacques Kiladjian

Blood Adv (2020) 4 (15): 3708–3715.

https://doi.org/10.1182/bloodadvances.2020002414

Published: 2020

Includes: Supplemental data

Journal Articles

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Blood Adv (2019) 3 (21): 3196–3200.

https://doi.org/10.1182/bloodadvances.2019000646

Published: 2019

Includes: Supplemental data

NARROW

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

Inference of genomic lesions from single-cell RNA-seq in myeloma improves functional intraclonal and interclonal analysis

Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis

COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis

Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only